Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study

ABSTRACT This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only.

Download Full-text

Future prospects for breast cancer immunotherapy

Medical Council ◽

10.21518/2079-701x-2018-19-12-16 ◽

2018 ◽

pp. 12-16

Author(s):

V. F. Semiglazov ◽

A. I. Tseluiko ◽

R. V. Donskikh ◽

P. V. Krivorotko ◽

G. A. Dashyan ◽

...

Keyword(s):

Breast Cancer ◽

Cell Death ◽

Monoclonal Antibodies ◽

Surgical Treatment ◽

Programmed Cell Death ◽

T Lymphocyte ◽

Standard Treatment ◽

Immune Checkpoints ◽

Future Prospects ◽

Programmed Cell Death 1

Immunotherapy has already become an important component of the standard treatment of patients with advanced cancer. Most treatment methods include monoclonal antibodies (mAbs) that block immune checkpoints, in particular, the programmed cell death 1 (PD-1) receptor and its ligand 1 (PD-L1) or are directed against T-lymphocyte-associated protein 4 (CTLA-4). The future prospects for immuno-oncology will be to determine whether these agents can be more effective if administered in a postoperative adjuvant or in a neoadjuvant regimen prior to surgical treatment. Vaccine therapy has shown promising results, and this therapy is especially attractive due to absence of pronounced toxicity.

Download Full-text

Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab

Therapeutic Advances in Hematology ◽

10.1177/2040620717695723 ◽

2017 ◽

Vol 8 (5) ◽

pp. 175-180 ◽

Cited By ~ 4

Author(s):

Nathan D. Gay ◽

Craig Y. Okada ◽

Andy I. Chen ◽

Emma C. Scott

Keyword(s):

Cell Death ◽

Programmed Cell Death ◽

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

Post Transplantation ◽

Future Directions ◽

Hematopoietic Stem ◽

Programmed Cell Death 1 ◽

Accelerated Approval ◽

Immunoglobulin Gamma

Nivolumab is a humanized immunoglobulin gamma-4 kappa anti-programmed cell death 1 monoclonal antibody that is currently approved in the treatment of several solid tumors and recently gained accelerated approval in classical Hodgkin lymphoma (cHL) that has relapsed or progressed following autologous hematopoietic stem-cell transplantation and post-transplantation brentuximab vedotin. The purpose of this article is to review the immunophysiologic basis, clinical efficacy, and toxicity of nivolumab in the treatment of cHL. In addition, we will review ongoing clinical trials and potential future directions of checkpoint inhibition in the treatment of cHL.

Download Full-text

Residue Specific Binding Analysis of PD-L1 to Its Monoclonal Antibodies by Computational Alanine Scanning

Physical Chemistry Chemical Physics ◽

10.1039/d1cp01281a ◽

2021 ◽

Author(s):

Wei Wen ◽

Dading Huang ◽

Jinxiao Bao ◽

John Z.H. Zhang

Keyword(s):

T Cells ◽

Cell Death ◽

Monoclonal Antibodies ◽

Programmed Cell Death ◽

Cancer Patients ◽

Specific Binding ◽

Checkpoint Proteins ◽

Programmed Cell Death 1 ◽

Computational Alanine Scanning ◽

Immune Checkpoint Proteins

Programmed cell death 1 receptor (PD-1) on the surface of T cells and its ligand 1 (PD-L1) are immune checkpoint proteins. Treating cancer patients with inhibitors blocking this checkpoint has...

Download Full-text